These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 39004098)

  • 41. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate.
    Chen EY; Raghunathan V; Prasad V
    JAMA Intern Med; 2019 Jul; 179(7):915-921. PubMed ID: 31135822
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus France.
    Drummond M; de Pouvourville G; Jones E; Haig J; Saba G; Cawston H
    Pharmacoeconomics; 2014 May; 32(5):509-20. PubMed ID: 24599784
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017.
    Chen AJ; Hu X; Conti RM; Jena AB; Goldman DP
    Value Health; 2019 Dec; 22(12):1387-1395. PubMed ID: 31806195
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric?
    Mason A; Drummond M; Ramsey S; Campbell J; Raisch D
    J Clin Oncol; 2010 Jul; 28(20):3234-8. PubMed ID: 20498408
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022.
    Mousavi I; Olivier T; Prasad V
    JAMA Netw Open; 2022 Jun; 5(6):e2216058. PubMed ID: 35687338
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
    Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
    Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of assessments conducted by the Canadian Agency for Drugs and Technologies in Health.
    Balijepalli C; Gullapalli L; Joshy J; Rawson NS
    J Comp Eff Res; 2024 May; 13(5):e230178. PubMed ID: 38567953
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis.
    Vokinger KN; Hwang TJ; Carl DL; Laube Y; Ludwig WD; Naci H; Kesselheim AS
    Lancet Oncol; 2022 Apr; 23(4):514-520. PubMed ID: 35271804
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.
    Michaeli DT; Michaeli T; Albers S; Boch T; Michaeli JC
    Eur J Health Econ; 2024 Aug; 25(6):979-997. PubMed ID: 37962724
    [TBL] [Abstract][Full Text] [Related]  

  • 50. U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review.
    Arora S; Narayan P; Ison G; Berman T; Suzman DL; Wedam S; Prowell TM; Ghosh S; Philip R; Osgood CL; Gao JJ; Shah M; Krol D; Wahby S; Royce M; Brus C; Bloomquist EW; Fiero MH; Tang S; Pazdur R; Ibrahim A; Amiri-Kordestani L; Beaver JA
    Clin Cancer Res; 2022 Mar; 28(6):1058-1071. PubMed ID: 34711631
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines.
    Salas-Vega S; Iliopoulos O; Mossialos E
    JAMA Oncol; 2017 Mar; 3(3):382-390. PubMed ID: 28033447
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Determinants of the Cancer Drug Funding Process in Canada.
    Gotfrit J; Jackson A; Shin JJW; Stewart DJ; Mallick R; Wheatley-Price P
    Curr Oncol; 2022 Mar; 29(3):1997-2007. PubMed ID: 35323362
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differences in cancer drug assessment between Spain and the United Kingdom.
    Lozano-Blázquez A; Dickson R; Fraga-Fuentes MD; Martínez-Martínez F; Calleja-Hernández MÁ
    Eur J Cancer; 2015 Sep; 51(13):1843-52. PubMed ID: 26119375
    [TBL] [Abstract][Full Text] [Related]  

  • 54. U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program.
    de Claro RA; Gao JJ; Kim T; Kluetz PG; Theoret MR; Beaver JA; Pazdur R
    Clin Cancer Res; 2021 Jan; 27(1):11-14. PubMed ID: 32816899
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative Assessment of Reimbursement Recommendations by NICE and HAS for Oncology New Medicines Indicated for the Treatment of Solid Tumors from 2015 to 2021.
    Trouiller JB; Laramée P
    Med Decis Making; 2023; 43(7-8):961-972. PubMed ID: 37480275
    [TBL] [Abstract][Full Text] [Related]  

  • 56. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
    Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
    Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.
    Davis C; Naci H; Gurpinar E; Poplavska E; Pinto A; Aggarwal A
    BMJ; 2017 Oct; 359():j4530. PubMed ID: 28978555
    [No Abstract]   [Full Text] [Related]  

  • 58. Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117395
    [No Abstract]   [Full Text] [Related]  

  • 59. Reforms to the patented medicine prices review board and the introduction of new drugs in Canada: An observational study.
    Lexchin J
    Health Policy; 2022 Oct; 126(10):1018-1022. PubMed ID: 35970691
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.
    Bloem LT; Vreman RA; Peeters NWL; Hoekman J; van der Elst ME; Leufkens HGM; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
    Clin Transl Sci; 2021 Jul; 14(4):1566-1577. PubMed ID: 33786991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.